Personal information

Carcinogenesis, Computational biology, molecular modeling, drug design

Biography

I attended Ekiti state university, Ado-Ekiti, Nigeria where
I bagged my B.Sc award in Biochemistry. My interest in cancer research made me proceed to the University of Ibadan for my M.Sc degree in Biochemistry with a specialization in Cancer Research and Molecular Biology. However, during the course of my masters' program, I acquired basic skills in computational biology such as molecular modeling, molecular docking, structural analysis. This motivated me to proceed for my Ph.D. in computational biology and currently, I am undertaking my Ph.D. study at the Molecular Bio-Computation and Drug Design Laboratory, Department of Pharmaceutical Chemistry, School of Health Sciences, Kwazulu-Natal University, Durban, South Africa, under the esteemed supervision of Prof. Mahmoud Soliman. My research focus is to mirror biological processes such as drug binding and mutational occurrences relative to their molecular implications in a wide range of diseases. This is to enhance broad-spectrum drug design and discovery processes, most especially for 'difficult-to-treat' diseases. During my Ph.D. I served as the research assistant playing various academic, supervisory and mentorship roles. I concluded my Ph.D. studies with outstanding outputs measured by high-impact scientific articles and distinguished individual awards. I worked as a post-doctoral researcher at the Molecular Bio-computation and Drug Design Lab, UKZN. Currently, I am working as a postdoctoral drug discovery scientist at the Research Unit in Bioinformatics (RUBi) group, Rhodes University, South Africa, under the esteemed supervision of Prof. Ozlem Tastan Bishop.

Activities

Employment (3)

Research Unit in Bioinformatics (RUBi), Rhodes University: Makhanda, Eastern Cape, ZA

2021-04-01 to present | Post-doctoral Drug Discovery Scientist (Biochemistry and Microbiology)
Employment
Source: Self-asserted source
Fisayo Olotu

University of KwaZulu-Natal: Durban, KwaZulu-Natal, ZA

2019-05-05 to 2021-03-24 | Post-Doctoral Researcher (Molecular Bio-computation and Drug Design Laboratory, Department of Pharmaceutical Chemistry)
Employment
Source: Self-asserted source
Fisayo Olotu

University of KwaZulu-Natal: Durban, KwaZulu-Natal, ZA

2017-06-25 to 2019-05-24 | Research Assistant (Molecular Modeling and Drug Design, Pharmaceutical chemistry )
Employment
Source: Self-asserted source
Fisayo Olotu

Education and qualifications (3)

University of KwaZulu-Natal: Durban, KwaZulu-Natal, ZA

2017-01-01 to 2019-05-24 | Ph.D. (Pharmaceutical chemistry)
Education
Source: Self-asserted source
Fisayo Olotu

University of Ibadan: Ibadan, Oyo , NG

2014-07 to 2016-04 | MSc (Biochemistry)
Education
Source: Self-asserted source
Fisayo Olotu

Ekiti State University: Ado-Ekiti, Ekiti State, NG

2007-07-09 to 2011-12-03 | BSc (Biochemistry)
Education
Source: Self-asserted source
Fisayo Olotu

Works (41)

WITHDRAWN: From a Computational Perspective: Elucidating the Neurotherapeutic and Inhibitory Properties of LRRK2 Kinase Domain by a Benzothiazole-based Compound

Current Pharmaceutical Biotechnology
2025-01-06 | Journal article
Contributors: Temitayo I. Subair; Opeyemi S. Soremekun; Fisayo A. Olotu; Mahmoud E. S. Soliman
Source: check_circle
Crossref

Potential Opportunities for Pharmacogenetic-Based Therapeutic Exploitation of Xanthine Dehydrogenase in Cardiovascular Disease

Antioxidants
2024-11-22 | Journal article
Contributors: Gianmichele Massimo; Nicki Dyson; Fisayo Olotu; Rayomand S. Khambata; Amrita Ahluwalia
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives

Current Pharmaceutical Biotechnology
2022-03 | Journal article
Contributors: Oluwole B. Akawa; Opeyemi S. Soremekun; Fisayo A. Olotu; Mahmoud E.S. Solima
Source: check_circle
Crossref

A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase

Journal of Molecular Modeling
2021-02 | Journal article
Contributors: Kehinde F. Omolabi; Emmanuel A. Iwuchukwu; Clement Agoni; Fisayo A. Olotu; Mahmoud E. S. Soliman
Source: check_circle
Crossref

In Silico Repurposing of J147 for Neonatal Encephalopathy Treatment: Exploring Molecular Mechanisms of Mutant Mitochondrial ATP Synthase

Current Pharmaceutical Biotechnology
2020-12-07 | Journal article
Contributors: Iwuchukwu A. Emmanuel; Fisayo A. Olotu; Clement Agoni; Mahmoud E.S. Soliman
Source: check_circle
Crossref

Tweaking α-Galactoceramides: Probing the Dynamical Mechanisms of Improved Recognition for Invariant Natural Killer T-cell Receptor in Cancer Immunotherapeutics

Current Pharmaceutical Biotechnology
2020-11-28 | Journal article
Contributors: Houda Washah; Clement Agoni; Fisayo A. Olotu; Geraldene Munsamy; Mahmoud E.S. Soliman
Source: check_circle
Crossref

CF3-pyridinyl substitution on anti-malarial therapeutics: Probing differential ligand binding and dynamical inhibitory effects of a novel triazolopyrimidine-based inhibitor on Plasmodium falciparum Dihydroorotate dehydrogenase.

Chemistry & biodiversity
2019-10 | Journal article
Contributors: Agoni C; Salifu EY; Munsamy G; Olotu FA; Soliman M
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.

Anti-cancer agents in medicinal chemistry
2019-10 | Journal article
Contributors: Peters XQ; Malinga TH; Agoni C; Olotu FA; E S Soliman M
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib.

Future medicinal chemistry
2019-09 | Journal article
Contributors: Aljoundi AK; Agoni C; Olotu FA; Soliman ME
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

From the Explored to the Unexplored: Computer-Tailored Drug Design Attempts in the Discovery of Selective Caspases Inhibitors.

Combinatorial chemistry & high throughput screening
2019-09 | Journal article
Contributors: Oduro RK; Issahakua AR; Soremekun OS; Agoni C; Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.

European journal of medicinal chemistry
2019-09 | Journal article
Contributors: Jing L; Wu G; Hao X; Olotu FA; Kang D; Chen CH; Lee KH; Soliman MES; Liu X; Song Y et al.
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Same Target, Different Therapeutic Outcome: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma.

Combinatorial chemistry & high throughput screening
2019-09 | Journal article
Contributors: Issahaku AR; Agoni C; Soremekun OS; Kubi PA; Oduro RK; Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Probing Binding Landscapes and Molecular Recognition Mechanisms of Atypical Antipsychotic Drugs towards the Selective Targeting of D2 Dopamine Receptor.

Molecular informatics
2019-08 | Journal article
Contributors: Appiah-Kubi P; Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Broadening the horizon: Integrative pharmacophore-based and cheminformatics screening of novel chemical modulators of mitochondria ATP synthase towards interventive Alzheimer's disease therapy.

Medical hypotheses
2019-06 | Journal article
Contributors: Emmanuel IA; Olotu F; Agoni C; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Revealing the distinct mechanistic binding and activity of 5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazole enantiomers against FGFR1.

Physical chemistry chemical physics : PCCP
2019-06 | Journal article
Contributors: Farrokhzadeh A; Akher FB; Olotu FA; Soliman MES; Van Heerden FR
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Deciphering the canonical blockade of activated Hageman Factor (FXIIa) by Benzamidine in the coagulation cascade: A thorough dynamical perspective.

Chemical biology & drug design
2019-05 | Journal article
Contributors: Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Drug promiscuity: Exploring the polypharmacology potential of 1, 3, 6-trisubstituted 1, 4-diazepane-7-ones as an inhibitor of the 'god father' of immune checkpoint.

Computational biology and chemistry
2019-05 | Journal article
Contributors: Soremekun OS; Olotu FA; Agoni C; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.

Journal of cellular biochemistry
2019-05 | Journal article
Contributors: Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Deciphering the "elixir of life": Dynamic perspectives into the allosteric modulation of mitochondrial ATP synthase by J147, a novel drug in the treatment of Alzheimer's disease.

Chemistry & biodiversity
2019-04 | Journal article
Contributors: Emmanuel IA; Olotu FA; Agoni C; Soliman M
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Turning to Computer-Aided Drug Design in the treatment of Diffuse Large B-cell Lymphoma: Has it been helpful?

Anti-cancer agents in medicinal chemistry
2019-04 | Journal article
Contributors: Aljoundi AK; Agoni C; Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

The irony of chirality - unveiling the distinct mechanistic binding and activities of 1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one enantiomers as irreversible covalent FGFR4 inhibitors.

Organic & biomolecular chemistry
2019-01 | Journal article
Contributors: Badichi Akher F; Farrokhzadeh A; Olotu FA; Agoni C; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Does Size Really Matter? Probing the Efficacy of Structural Reduction in the Optimization of Bioderived Compounds - A Computational "Proof-of-Concept".

Computational and structural biotechnology journal
2018-11 | Journal article
Contributors: Olotu FA; Munsamy G; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Covalent simulations of covalent/irreversible enzyme inhibition in drug discovery: a reliable technical protocol.

Future medicinal chemistry
2018-10 | Journal article
Contributors: Khan S; Bjij I; Olotu FA; Agoni C; Adeniji E; S Soliman ME
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Exploring the C-terminal tail dynamics: Structural and molecular perspectives into the therapeutic activities of novel CRMP-2 inhibitors, Naringenin and Naringenin-7-O- glucuronide, in the treatment of Alzheimer's disease.

Chemistry & biodiversity
2018-10 | Journal article
Contributors: Lawal M; Olotu F; Agoni C; Soliman M
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Microbes, not humans: exploring the molecular basis of Pseudouridimycin selectivity towards bacterial and not human RNA polymerase.

Biotechnology letters
2018-10 | Journal article
Contributors: Rabbad AH; Agoni C; Olotu FA; Soliman ME
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

An update on the discovery and development of selective heat shock protein inhibitors as anti-cancer therapy.

Expert opinion on drug discovery
2018-09 | Journal article
Contributors: Olotu F; Adeniji E; Agoni C; Bjiji I; Khan S; Elrashedy A; Soliman M
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy.

Journal of cellular biochemistry
2018-08 | Journal article
Contributors: Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central
grade
Preferred source (of 2)‎

Probing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 Proteins.

Applied biochemistry and biotechnology
2018-08 | Journal article
Contributors: Olotu FA; Agoni C; Adeniji E; Abdullahi M; Soliman ME
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Solving the riddle: Unraveling the mechanisms of blocking the binding of leukotoxin by therapeutic antagonists in periodontal diseases.

Journal of cellular biochemistry
2018-08 | Journal article
Contributors: Abdullahi M; Olotu FA; Soliman ME
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central
grade
Preferred source (of 2)‎

A novel compound purified from Alstonia boonei inhibits Plasmodium falciparum Lactate dehydrogenase and Plasmepsin II.

Journal of biomolecular structure & dynamics
2018-07 | Journal article
Contributors: Olanlokun JO; Olotu AF; David OM; Idowu TO; Soliman ESM; Olorunsogo OO
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Across the blood-brain barrier: Neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer's disease using bioinformatics and computational tools.

Computers in biology and medicine
2018-07 | Journal article
Contributors: Lawal M; Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Covalent Inhibition in Drug Discovery: Filling the Void in Literature.

Current topics in medicinal chemistry
2018-07 | Journal article
Contributors: Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Exploring the lapse in druggability: Sequence Analysis, Structural Dynamics and binding site characterization of K-RasG12C variant, a feasible oncotherapeutics target.

Anti-cancer agents in medicinal chemistry
2018-07 | Journal article
Contributors: Adeniji EA; Olotu FA; Soliman M
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Alcohol Metabolic Inefficiency: Structural Characterization of Polymorphism-Induced ALDH2 Dysfunctionality and Allosteric Site Identification for Design of Potential Wildtype Reactivators.

The protein journal
2018-04 | Journal article
Contributors: Adeniji EA; Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Allosteric inhibition abrogates dysregulated LFA-1 activation: Structural insight into mechanisms of diminished immunologic disease.

Computational biology and chemistry
2018-04 | Journal article
Contributors: Abdullahi M; Olotu FA; Soliman ME
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Cover Image, Volume 119, Number 3, March 2018.

Journal of cellular biochemistry
2018-03 | Journal article
Contributors: Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.

Chemistry & biodiversity
2018-03 | Journal article
Contributors: El Rashedy AA; Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.

Journal of cellular biochemistry
2018-03 | Journal article
Contributors: Olotu FA; Soliman MES
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Dynamics of allosteric modulation of lymphocyte function associated antigen-1 closure-open switch: unveiling the structural mechanisms associated with outside-in signaling activation.

Biotechnology letters.
2017-12 | Journal article
Contributors: Abdullahi M; Olotu FA; Soliman ME
Source: Self-asserted source
Fisayo Olotu via Europe PubMed Central

Isoniazid Induced Toxicites and Idiosyncratic Responses in Male Albino Wistar Rats

Journal of Cancer Research Updates
2017-06-14 | Journal article
Source: Self-asserted source
Fisayo Olotu

Chronic Coartem treatment and hepatocarcinogenesis in male Wistars rat

Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26
2016-04-07 | Conference abstract
Source: Self-asserted source
Fisayo Olotu

Peer review (1 review for 1 publication/grant)

Review activity for International journal of peptide research and therapeutics. (1)